1 Min Read
July 5 (Reuters) - Cynata Therapeutics Ltd
* Received written advice from US FDA regarding regulatory approval path for Cynata’s proprietary cymerus™ mesenchymal stem cell (MSC) products Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.